Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
Ruth M de TuteCharlotte PawlynDavid A CairnsFaith E DaviesTom MenziesAndrew C RawstronJohn R JonesAnna HockadayRowena HendersonCurly T C M MorrisMark T DraysonMatthew W JennerMartin F KaiserWalter M GregoryGareth J MorganGraham H JacksonRoger G OwenPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
In patients with multiple myeloma, MRD status at both ASCT + 3 and ASCT + 9 is a powerful predictor of PFS and OS.